Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resmetirom - Madrigal Pharmaceuticals

Next Previous
Drug Profile

Resmetirom - Madrigal Pharmaceuticals

Alternative Names: MGL-3196; Rezdiffra; VIA-3196

Latest Information Update: 21 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Madrigal Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Chlorinated hydrocarbons; Ethers; Hepatoprotectants; Ketones; Nitriles; Pyridazines; Small molecules; Triazines
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-alcoholic steatohepatitis
  • Discontinued Hyperlipoproteinaemia type IIa

Most Recent Events

  • 16 Oct 2025 Sagimet Biosciences completes enrolment in its phase I trial in healthy participants in USA (NCT07216313)
  • 16 Aug 2025 Registered for Non-alcoholic steatohepatitis in Norway, Liechtenstein, Iceland, European Union (PO)
  • 05 Aug 2025 The U.S. Patent and Trademark Office (USPTO) grants a new patent entitled, “Methods for treating a fatty liver disease” to Madrigal Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top